摘要
目的比较米氮平与舍曲林治疗抑郁症的临床疗效与安全性。方法对分别接受米氮平和舍曲林的66例抑郁症患者进行为期6周的观察,并应用17项汉密尔顿抑郁量表(HAMD-17)和TESS量表评估和比较这两种药物治疗抑郁症的疗效和安全性。结果治疗1周后,米氮平组的HAMD评分低于舍曲林组,差异有显著性(P<0.05)。治疗6周后,米氮平组有效率和治愈率分别为91.6%和62.5%,与舍曲林组(88.2%和61.8%)比较无显著性差异(P>0.05)。与舍曲林组相比,米氮平组每次TESS评分均低于舍曲林组,差异有显著性(P<0.05)。结论米氮平是一种安全、有效的新型抗抑郁药物,起效较快。
Objective To evaluate the therapeutic effect and safety of mirtazapine and sertraline in treatment of depression. Methods 66 patients with diagnosis of depressive disorder according to ICD - 10 criteria were randomized into mirtazapine group and sertraline group, which were treated with mirtazapine （15 -45mg/d） and sertraline （20 - 40mg/d） respectively for 6 weeks. Atidepressive effect and side effect were evaluated with 17 - item Hamilton depression rating scale for depresssion （ HAMD - 17 ） and treatment emergent symptom scale （TESS）. Results At the end of 1 st week, the score of HAMD in mirtazapine group was significantly lower than in sertraline group （ P 〈 0.05 ）. At the end of 6th week, there were no significant differences in effective rate （ 91.6% vs 88.2% ） or recovery rate （62.5% vs 61. 8% ） between mirtazapine group and sertraline group （P 〉 0. 05）. The scores of TESS at every viewpoints in mirtazapine group were significantly lower than those in sertraline group （ P 〈 0.05 ）. Conclusion Mirtazapine is a safe, effective antidepressant with rapid response.
出处
《精神医学杂志》
2011年第1期34-36,共3页
Journal of Psychiatry
关键词
米氮平
舍曲林
抑郁症
Mirtazapine Sertraline Depression
